Of Anthracycline - Articles
Anthracyclines: Does Stage Matter?
by
PinkRibbons ..
... ree to six months. We're gaining so much on the other end, that it appears worthwhile when you do those risk versus benefit analyses. CATHY CONLEY: Dr. Muss, what's the role of anthracyclines in both the adjuvant and metastatic settings? HYMAN B. MUSS, MD: Well, anthracyclines in the adjuvant setting -- by which we mean giving them to women with ...
Read on »
Will Targeted Therapies Work for CLL?
by
PinkRibbons ..
... nd certainly that's including evidence that anthracycline-containing therapy is actually more effective than non-anthracycline-containing therapy. CATHY CONLEY: The benefits of anthracyclines include longer survival and longer time to remission. But what about the differences between the anthracyclines epirubicin and doxorubicin? JOYCE O'SHAUGHNE ...
Read on »
Ixempra for ovarian cancer
by
Mark Levin
... mpra is specifically indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Ixempra monotherapy is specifically indicated fo ...
Read on »
The US Food and Drug Administrat ...
by
Medical Quack
... ved to treat patients with locally advanced breast cancer or with cancer that has started spreading to other parts of the body (metastatic), and is resistant or refractory to anthracyclines, taxanes, and capecitabine.FDA Approves Chemotherapy Drug Ixempra For Advanced Breast Cancer
Read on »
Weekly Taxol for uterine cancer
by
Mark Levin
... table for many patients. More intense combination chemotherapy significantly improves the disease-free survival and the data indicate a modest improvement in OS. The addition of anthracyclines (e.g. doxorubicin) or the taxanes [e.g. paclitaxel (Taxol)] to cisplatin increases the response rate. While no one drug or regimen offers a clear benefit for ...
Read on »
Amrubicin for small cell lung cancer
by
Mark Levin
Amrubicin, previously known as SM-5887, is an anthracycline used in the treatment of lung cancer. It is marketed in Japan since 2002 by Sumitomo Pharmaceuticals under the brand name Calsed. Two phase 2 studies of amrubici ...
Read on »
Xeloda and Taxotere
by
Mark Levin
... his regimen was FDA approved on the basis of a phase III study of docetaxel monotherapy and docetaxel plus capecitabine for metastatic breast cancer patients who had received anthracyclines. The overall response rate of the combination group was 42%(n=255), and that of the monotherapy group was 30%(n=256)(p=0.006). The primary endpoints were time t ...
Read on »
I want to live longer than you ...
by
Angus
... ling of the ankles and a dry cough. Epidemiology and risk factors Much debate here. But the following seem to be badly prognostic in no particular order: a cumulative dosage of anthracyclines above 300 mg/m2 of body surface area (Kezia has received 315 mg/m2), female sex (as they tend to have more fat and anthracyclines are not absorbed in body fa ...
Read on »
